PL2880053T3 - Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4 - Google Patents

Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4

Info

Publication number: PL2880053T3
Authority: PL; Poland
Prior art keywords: tissue damage; via anti; fibrosis via; mitigating tissue; ltbp4
Prior art date: 2012-08-01

Application number

PL13835243T

Other languages

English (en)

Inventor

Elizabeth M. MCNALLY

Ahlke HEYDEMANN

Ermelinda CECO

Original Assignee

Ikaika Therapeutics, Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-01

Filing date

2013-08-01

Publication date

2021-01-11

2013-08-01 Application filed by Ikaika Therapeutics, Llc filed Critical Ikaika Therapeutics, Llc

2021-01-11 Publication of PL2880053T3 publication Critical patent/PL2880053T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL13835243T 2012-08-01 2013-08-01 Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4 PL2880053T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261678564P	2012-08-01	2012-08-01
PCT/US2013/053255 WO2014039189A1 (en)	2012-08-01	2013-08-01	Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
EP13835243.0A EP2880053B8 (en)	2012-08-01	2013-08-01	Mitigating tissue damage and fibrosis via anti-ltbp4 antibody

Publications (1)

Publication Number	Publication Date
PL2880053T3 true PL2880053T3 (pl)	2021-01-11

Family

ID=50025687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13835243T PL2880053T3 (pl)	2012-08-01	2013-08-01	Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4

Country Status (14)

Country	Link
US (12)	US9873739B2 (pl)
EP (2)	EP3711771B1 (pl)
AU (6)	AU2013313282B2 (pl)
CA (1)	CA2880649C (pl)
CY (1)	CY1123029T1 (pl)
DK (1)	DK2880053T3 (pl)
ES (2)	ES2791778T3 (pl)
HR (1)	HRP20200818T1 (pl)
HU (1)	HUE049217T2 (pl)
PL (1)	PL2880053T3 (pl)
PT (1)	PT2880053T (pl)
RS (1)	RS60318B1 (pl)
SI (1)	SI2880053T1 (pl)
WO (1)	WO2014039189A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201609207SA (en) *	2014-05-13	2016-12-29	Univ Pennsylvania	Compositions comprising aav expressing dual antibody constructs and uses thereof
WO2016054155A1 (en) *	2014-09-30	2016-04-07	Primegen Biotech, Llc.	Treatment of fibrosis using deep tissue heating and stem cell therapy
KR20160101692A (ko)	2015-02-17	2016-08-25	한국전자통신연구원	다채널 신호 처리 방법 및 상기 방법을 수행하는 다채널 신호 처리 장치
CN108135994B (zh)	2015-05-13	2022-01-25	宾夕法尼亚州大学信托人	Aav-介导的抗-流感抗体的表达及其使用方法
JOP20190200A1 (ar)	2017-02-28	2019-08-27	Univ Pennsylvania	تركيبات نافعة في معالجة ضمور العضل النخاعي
SG11201907611WA (en)	2017-02-28	2019-09-27	Univ Pennsylvania	Influenza vaccines based on aav vectors
US11827906B2 (en)	2017-02-28	2023-11-28	The Trustees Of The University Of Pennsylvania	Adeno-associated virus (AAV) clade f vector and uses therefor
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20210308273A1 (en)	2018-08-02	2021-10-07	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2021533200A (ja)	2018-08-02	2021-12-02	ダインセラピューティクス, インコーポレーテッドDyne Therapeutics, Inc.	顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US11168141B2 (en)	2018-08-02	2021-11-09	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20210117271A (ko)	2018-12-21	2021-09-28	노쓰웨스턴유니버시티	근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
WO2020139977A1 (en)	2018-12-26	2020-07-02	Northwestern University	Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US11969475B2 (en)	2021-07-09	2024-04-30	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20250159196A (ko) *	2023-02-27	2025-11-10	다인 세라퓨틱스, 인크.	근육내 섬유증의 진행을 억제하기 위한 방법 및 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
US5372807A (en)	1990-05-14	1994-12-13	University Of Medicine And Dentistry Of New Jersey	Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5637459A (en)	1990-06-11	1997-06-10	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: chimeric selex
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5994618A (en)	1997-02-05	1999-11-30	Johns Hopkins University School Of Medicine	Growth differentiation factor-8 transgenic mice
CA2157577C (en)	1993-03-19	2009-11-17	Se-Jin Lee	Growth differentiation factor-8
US6891082B2 (en)	1997-08-01	2005-05-10	The Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en)	1998-02-19	2002-04-09	Metamorphix International, Inc.	Myostatin multimers
US6004937A (en)	1998-03-09	1999-12-21	Genetics Institute, Inc.	Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
BR0008188A (pt)	1999-01-21	2002-02-13	Metamorphix Inc	Inibidores de fator de diferenciação de crescimento e usos para os mesmos
DE60001229T2 (de)	1999-04-09	2003-10-30	Smithkline Beecham Corp., Philadelphia	Triarylimidazole
EE200200025A (et)	1999-07-20	2003-04-15	Pharmexa A/S	Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
WO2001053350A1 (en)	2000-01-18	2001-07-26	Agresearch Limited	Myostatin and mimetics thereof
AR029803A1 (es)	2000-02-21	2003-07-16	Smithkline Beecham Plc	Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
WO2002040468A1 (en)	2000-11-16	2002-05-23	Smithkline Beecham Corporation	Compounds
GB0102668D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
TW200526779A (en)	2001-02-08	2005-08-16	Wyeth Corp	Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en)	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
MXPA04008150A (es)	2002-02-21	2005-06-17	Wyeth Corp	Gasp1: una proteina que contiene dominio de folistatina.
MXPA04008149A (es)	2002-02-21	2005-06-17	Wyeth Corp	Proteinas que contienen dominios de folistatina.
BR0314270A (pt)	2002-09-16	2005-08-02	Univ Johns Hopkins	Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina
US7261893B2 (en)	2002-10-22	2007-08-28	Wyeth	Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en)	2002-10-25	2004-11-11	Wolfman Neil M.	ActRIIB fusion polypeptides and uses therefor
EP2272864A3 (en)	2002-12-20	2011-02-16	Amgen Inc.	Binding agents which inhibit myostatin
WO2004083241A2 (en)	2003-03-19	2004-09-30	Takeda Pharmaceutical Company Limited	Btc-interacting proteins and use thereof
EP1729793B1 (en)	2004-03-02	2015-07-22	Acceleron Pharma Inc.	Alk7 and myostatin inhibitors for muscle wasting disorders
AU2005227896B2 (en)	2004-03-23	2008-11-13	Eli Lilly And Company	Anti-myostatin antibodies
ATE498685T1 (de)	2004-06-28	2011-03-15	Univ Western Australia	Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
ES2551852T3 (es)	2004-07-23	2015-11-24	Acceleron Pharma Inc.	Polipéptidos del receptor ActRII
CA2576734C (en)	2004-07-29	2010-03-16	Schering-Plough Ltd.	Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
EA201100642A1 (ru)	2005-04-25	2011-12-30	Пфайзер Инк.	Антитела к миостатину
MX2011000655A (es) *	2008-07-18	2011-03-21	Oragenics Inc	Composiciones para la deteccion y tratamiento de cancer colorrectal.
US8084601B2 (en)	2008-09-11	2011-12-27	Royal Holloway And Bedford New College Royal Holloway, University Of London	Oligomers
FR2943249B1 (fr)	2009-03-18	2011-08-12	Genethon	Utilisation de la decorine pour augmenter la masse musculaire
EP2424560A4 (en)	2009-03-23	2013-11-27	Inst Medical W & E Hall	COMPOUNDS AND METHOD FOR MODULATING THE IMMUNE REACTION
CN102459597B (zh)	2009-05-08	2020-06-30	库尔纳公司	通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
WO2012006181A2 (en)	2010-06-29	2012-01-12	Mount Sinai School Of Medicine	Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer

2013
- 2013-08-01 ES ES13835243T patent/ES2791778T3/es active Active
- 2013-08-01 DK DK13835243.0T patent/DK2880053T3/da active
- 2013-08-01 EP EP20152849.4A patent/EP3711771B1/en active Active
- 2013-08-01 WO PCT/US2013/053255 patent/WO2014039189A1/en not_active Ceased
- 2013-08-01 EP EP13835243.0A patent/EP2880053B8/en active Active
- 2013-08-01 HU HUE13835243A patent/HUE049217T2/hu unknown
- 2013-08-01 ES ES20152849T patent/ES3047691T3/es active Active
- 2013-08-01 SI SI201331718T patent/SI2880053T1/sl unknown
- 2013-08-01 US US13/957,100 patent/US9873739B2/en active Active
- 2013-08-01 RS RS20200604A patent/RS60318B1/sr unknown
- 2013-08-01 AU AU2013313282A patent/AU2013313282B2/en active Active
- 2013-08-01 PL PL13835243T patent/PL2880053T3/pl unknown
- 2013-08-01 CA CA2880649A patent/CA2880649C/en active Active
- 2013-08-01 PT PT138352430T patent/PT2880053T/pt unknown
- 2013-08-01 HR HRP20200818TT patent/HRP20200818T1/hr unknown
2017
- 2017-12-28 US US15/857,122 patent/US20180134785A1/en not_active Abandoned
2018
- 2018-01-04 AU AU2018200078A patent/AU2018200078A1/en not_active Abandoned
- 2018-09-05 US US16/122,333 patent/US20190002557A1/en not_active Abandoned
2019
- 2019-04-23 US US16/392,108 patent/US20190256589A1/en not_active Abandoned
- 2019-08-28 AU AU2019222850A patent/AU2019222850A1/en not_active Abandoned
- 2019-12-16 US US16/716,382 patent/US20200123247A1/en not_active Abandoned
2020
- 2020-05-25 CY CY20201100496T patent/CY1123029T1/el unknown
- 2020-08-14 US US16/994,225 patent/US20200385457A1/en not_active Abandoned
2021
- 2021-02-08 AU AU2021200783A patent/AU2021200783B2/en active Active
- 2021-03-31 US US17/219,845 patent/US20210238274A1/en not_active Abandoned
- 2021-11-29 US US17/536,768 patent/US20220089717A1/en not_active Abandoned
2022
- 2022-07-07 US US17/811,233 patent/US20230235044A1/en not_active Abandoned
- 2022-11-15 AU AU2022271391A patent/AU2022271391A1/en not_active Abandoned
2024
- 2024-04-25 US US18/646,068 patent/US20240287171A1/en not_active Abandoned
- 2024-07-17 AU AU2024204925A patent/AU2024204925A1/en active Pending
- 2024-12-13 US US18/980,341 patent/US20250109197A1/en not_active Abandoned
2025
- 2025-07-25 US US19/281,249 patent/US20250346664A1/en active Pending

Also Published As

Publication number	Publication date
US20210238274A1 (en)	2021-08-05
EP2880053B8 (en)	2020-04-15
EP3711771C0 (en)	2025-09-03
EP3711771A1 (en)	2020-09-23
CY1123029T1 (el)	2021-10-29
AU2024204925A1 (en)	2024-08-08
AU2021200783B2 (en)	2022-10-06
US20240287171A1 (en)	2024-08-29
US20200385457A1 (en)	2020-12-10
HK1211307A1 (en)	2016-05-20
US20190002557A1 (en)	2019-01-03
CA2880649A1 (en)	2014-03-13
AU2021200783A1 (en)	2021-03-04
AU2018200078A1 (en)	2018-01-25
AU2013313282A1 (en)	2015-02-26
AU2022271391A1 (en)	2022-12-15
HRP20200818T1 (hr)	2020-08-07
US20140037637A1 (en)	2014-02-06
US20230235044A1 (en)	2023-07-27
HUE049217T2 (hu)	2020-09-28
US20220089717A1 (en)	2022-03-24
EP2880053A4 (en)	2016-03-09
DK2880053T3 (da)	2020-05-11
CA2880649C (en)	2023-03-14
ES2791778T3 (es)	2020-11-05
AU2019222850A1 (en)	2019-09-19
RS60318B1 (sr)	2020-07-31
US9873739B2 (en)	2018-01-23
WO2014039189A1 (en)	2014-03-13
EP3711771B1 (en)	2025-09-03
EP2880053B1 (en)	2020-02-26
PT2880053T (pt)	2020-05-22
AU2013313282B2 (en)	2018-02-01
US20250109197A1 (en)	2025-04-03
SI2880053T1 (sl)	2020-08-31
US20250346664A1 (en)	2025-11-13
US20190256589A1 (en)	2019-08-22
ES3047691T3 (en)	2025-12-04
US20200123247A1 (en)	2020-04-23
US20180134785A1 (en)	2018-05-17
EP2880053A1 (en)	2015-06-10

Publication	Publication Date	Title
SI2880053T1 (sl)	2020-08-31	Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4
IL230511A0 (en)	2014-03-31	4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL235826A0 (en)	2015-02-01	Diazaspirocycloalkane and azaspirocycloalkane
AP4055A (en)	2017-03-07	Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
GB201400072D0 (en)	2014-02-19	Implant and implant system
ZA201408594B (en)	2015-12-23	Xylitol-based anti-mucosal compositions and related methods and compositions
GB201110783D0 (en)	2011-08-10	Methods and uses
EP2693912A4 (en)	2014-08-13	ARTIFICIAL NAIL AND NAIL POLISH
GB201216649D0 (en)	2012-10-31	Agents and methods
EP2855769A4 (en)	2016-03-02	PAPER-MOUCHOIR COMPRISING MACROALGUES
GB201117106D0 (en)	2011-11-16	Prosthesis and methods and uses involving said prosthesis
GB201116774D0 (en)	2011-11-09	Uses and methods
EP2931140A4 (en)	2016-08-10	Tissue repair equipment and methods
IL229303A0 (en)	2014-01-30	Devices and methods to fasten tissue
EP2663343A4 (en)	2014-06-11	DEVICES AND METHODS FOR TISSUE ENGINEERING
GB2504303B (en)	2016-01-06	Earphones and earplugs
GB201108490D0 (en)	2011-07-06	Methods and uses
IL223436A (en)	2016-11-30	Methods for preparing tetranor - pgdm and tetranor - pgjm
GB201001384D0 (en)	2010-03-17	Light-fitting and associated methods
ME03310B (me)	2019-10-20	4-IMIDAZOPIRIDAZIN-1-jL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDl КАО INHIBITORI втк
TWM433704U (en)	2012-07-11	Slidable and rotatable hinge
TWM432399U (en)	2012-07-01	Improved earmuff structure
AU2012905160A0 (en)	2012-12-13	Implant and uses thereof
GB201006380D0 (en)	2010-06-02	Excipients and their use
GB201222541D0 (en)	2013-01-30	Kiddibidet and pottibidet